

## FINANCIAL SUPERVISION AUTHORITY

Current report No. 8/2019

Date prepared: 2019-04-03

Abbreviated name of the issuer: MABION S.A.

Subject: The update on development strategy of medicinal products.

Legal basis: Article 17 paragraph 1 MAR - confidential information.

### Contents of the report

With regard to Current Report No. 20/2017 of 30<sup>th</sup> of March 2017 about the adoption of the medicinal products development strategy, the Management Board of Mabion S.A. ("Company", "Issuer") informs that today it adopted, as a result of the annually conducted update of the abovementioned strategy, a resolution approving changes in the current strategy for medicinal products development.

In accordance with the adopted resolution, the catalog of projects, which the Company is interested to implement, either now or in the future, alone or with its partners, has changed. The company has also accomplished qualifications of research and development projects for three groups of projects, i.e. active projects, new projects planned for 2019 and partner projects.

### Active projects

The group of projects of the highest significance for the Company, in respect of which the Company conducts work and invests funds. This group includes currently implemented projects: MabionCD20, MabionMS and MabionEGFR.

### New projects planned for 2019

Projects, in respect of which the Company plans to commence research and development work in the second half of 2019. These will be projects related to three biosimilar medicines in the areas of autoimmunology, metabolic diseases and oncology.

### Partnership projects

Projects in the scope of which the Company is considering beginning the implementation in the moderate or long term, preferentially in cooperation with a partner. These will be projects concerning, among others, autoimmune and oncological diseases.

The company will continue to update its development strategy for medicinal products every year.